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Tumor necrosis factor-a receptor (TNFRI)-associated periodic syndrome (TRAPS) is the most
common autosomal-dominant autoinflammatory condition and is caused by mutations in the
TNFRSFIA gene. TRAPS is characterized by recurrent attacks of fever typically lasting from 1 to 3
weeks; in addition to fever, common clinical features include mainly periorbital oedema, conjunctivitis,
a migratory erythematous plaque simulating erysipela with underlying myalgia, and arthritis or
arthralgia; serosal membrane inflammation is also possible. The identification of TNFRSFIA mutations
as the genetic cause of TRAPS coincided with the wider use of biological agents in medicine and raised
the possibility that blocking TNF could potentially represent the primary therapeutic goal in TRAPS,
thus disclosing new treatment choices for this complex disease. In the past few years, isolated reports
and case-series have been published suggesting that inhibition of TNF-a might represent a promising
therapeutic approach in TRAPS. We present here our experience with etanercept in the treatment of
patients affected with TRAPS, and we also add a review of the literature.
Autoinflammatory disorders are defined by
spontaneously relapsing and remitting bouts of
systemic inflammation in the absence of pathogens,
autoantibodies, or antigen-specific T cells. These
disorders can be monogenic or multifactorial and
are associated with mutations of genes involved in
inflammation and apoptosis (I).
Among monogenic autoinflammatory diseases,
the tumor necrosis factor-receptor l-associated
periodic syndrome (TRAPS; OM1M 142680)
is the most common autosomal dominant
autoinflammatory disorder and is characterized by
recurrent attacks offever typically lasting from 1 to 3
weeks; in addition to fever, common clinical features
include mainly periorbital oedema, conjunctivitis, a
migratory erythematous plaque simulating erysipela
with underlying myalgia, and arthritis or arthralgia;
serosal membrane inflammation is also possible
(2-3). TRAPS is caused by mutations in the gene
TNFRSFIA, located on chromosome l2p13,
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Fig. I. Tumor Necrosis Factor-alpha (TNF-a) inhibitors and pathogenesis oftumor necrosis factor receptor-associated
periodic syndrome. Tumor Necrosis Factor Receptor Superfamily IA (TNFRSFIA) undergoes trimerization, and the
binding to trimeric TNF-a. induces either survival or apoptotic pathways. Upon receptor activation, TNF Receptor
Associated Factor (TRAF) is recruited via the adapter protein, TNF Receptor-Associated Death Domain (TRADD), to the
plasma membrane. This activation is importantfor cell survival and inflammatory signals. TRADD is also associated with
[as-associated death domain (FADD), which leads to the induction ofapoptosis via the recruitment and cleavage ofpro-
caspase 8. The monoclonal antibodies (i.e. irfliximab, ada/imumab) and the receptor analog (etanercept) bind to TNF-a.
and block it s interaction with TNFRSFIA. In particular, irfliximab and ada/imumab are chimeric antibodies including
mouse and human components. while etanercept is a soluble with p75 Tumor Necrosis Factor Receptor Superfamily IB
(TNFRSFlB)-/inked Fe human IgGI recombinant fusion protein. These agents are designed to bind circulating TNF-a,
thus preventing TNF-signa/ing and TNF-mediated inflammatory response.
encoding the 55-kD receptor for' tumor necrosis
factor-a (TNF-a) (TNFRSFIA) (4).
TNFRSF IA is a transmembrane glycoprotein
(Fig. I) which consists of an extracellular region
characterized by a distinct pattern of 4 cysteine-rich
domains (CRDs 1-4), a transmembrane region, and
an intracellular death domain (DD), which promotes
TNFRSF IA signaling (5). The binding site for TNFa
is formed by CRD2 and CRD3 (6), while CRDI is the
pre-ligand assembly binding domain and is thought
to mediate TNFRSF IA self-assembly (7). More than
40 individual mutations have been identified, the
majority of which are localised in the CRDI and
CRD2 domains (http://fmf.igh.cnrs.fr/infevers/) (8).
Most mutations described involve cysteine residues
and are associated with a higher disease penetrance,
however several variants involving other residues
have been reported (9). In vitro studies suggest that
these TRAPS-associated TNFRSF1A mutations are
responsible for altered TNFRSFIA expression,
impaired TNF-a binding and shedding (4), defective
trafficking (10-11) and abnormal apoptosis (3,12).
Typical of TRAPS is a wide variability amongst
patients both in terms of age of disease onset and
frequency, and length and severity of inflammatory
attacks. This heterogeneity is related to the complex
phenotypical expression of TRAPS and to the wide
spectrum of TNFRSF1A mutations (13).
Patients usually tend to develop a chronic
disease course with recurrent flares' of multi-organ
manifestations, with or without fever, as well as
persistently elevated acute-phase reactants, including
serum amyloid-A (SAA) circulating levels, C-
reactive protein (CRP), erythrocyte sedimentation
rate (ESR) and interleukin-6 (IL-6), and IL-8 (14).
Renal AA amyloidosis is the most serious long-
term complication of TRAPS, with a prevalence
ranging from 14% to 25%, mainly affecting, but not
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Table I. The table summarizes data from the entire cohort ofpatients enrolled.
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Pt Age at testing Age at onset Gender Mutations in Clinical Manifestations
(yrs) (yrs) TNFRSFIA
1 28 13 M '" Y103-R104 Recurrent pericarditisheterozygous
2 50 34 M R92Q Recurrent pericarditisheterozygous
3 32 28 F R92Q Recurrent pericarditisheterozygous
4 41 38 F R92Q Recurrent pericarditisheterozygous
DI2E Recurrent fever attacks, mild hepatomegaly and splenomegaly,5 II 7 F heterozygous lower limbs myalgia, conjunctivitis, erythematous rash (face) and
a maculopapular rash (trunk, ankles, lower limbs).
Recurrent fever attacks, lower limbs myalgia, thoracic and
6 29 9 F abdominal pain, periorbital oedema, erythematous rash involving
-" trunk and lower limbs and proteinuria (0,650 mg/L).
R92Q
7 27 26 F heterozygous Recurrent pericarditis, sacroileitis
Gender, age at disease onset, and the age at the time ofgenetic testing are shown. The results ofgenetic testing for
mutations of the gene responsible for the tumor necrosis factor-a receptor-associated periodic syndrome (TNFRSF 1A
gene) and the clinical manifestations are also listed. List ofabbreviations: Pt = patient; yrs = years; F = female; M "':;
male; *patient n.6 did not carry mutations, but showed a defective TNFRSF1A shedding (ref4) ., "i
limited to, patients who carry mutations involving
cysteine residues; patients carrying low penetrance
mutations may also develop reactive amyloidosis,
although they are usually characterized by a milder
disease, if they present a persistent acute phase
response (15-16).
Treatment strategies
Treatment of TRAPS proves more challenging
than other auto inflammatory syndromes due to the
wide genetic heterogeneity and to the protean clinical
phenotype: some patients experience significant
disability over time or develop signs of renal
amyloidosis, requiring novel treatment strategies
with the aim of better long-term disease control.
There are patients who gain some symptomatic relief
from high-dose non-steroidal anti-inflammatory
drugs, whilst colchicine or immunomodulators
such as methotrexate, cyclosporin and thalidomide
produce little benefit. Inflammatory attacks usually
respond to corticosteroid administration (17), but
often require increasing doses, especially in patients
with frequent relapses or continuous symptoms, who
become prone to metasteroidal co-morbidities (18).
The identification of TNFRSF1A mutations as the
genetic cause of TRAPS coincided with the wider
use of biological agents in medicine, thus disclosing
new treatment choices for this complex disease.
The fact of the defect in TNFRSF 1A shedding and
subsequent inappropriate TNF inhibition suggested
that blocking TNF - even though TNF is not
increased in most patients (14) - could potentially
represent the primary therapeutic goal in TRAPS
(19). Anti-TNF therapy in TRAPS has been based
on etanercept, a recombinant human TNFR (p75)-Fc
fusion protein comprising two receptors linked by
an IgG I Fe fragment. The exact therapeutic profile
and dosing regime of etanercept in the long-term
management of TRAPS, however, has yet to be
established.
The efficacy of etanercept has been shown in
single patients and/or in case-series of patients
of different ages with fully penetrant TRAPS
phenotypes, as evidenced by decreased frequency of
attacks and/or decreased severity of disease (20-21).
Even unusual manifestations such as non-suppurative
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panniculitis and small-vessel vasculitis were
controlled by etanercept in 2 adult patients (22). In
a recently reported case series of 7 patients affected
with TRAPS who were treated with etanercept for
24 weeks, although the drug did not completely
eliminate inflammatory attacks, it was able to
reduce disease activity, also in terms of acute-phase
response, and allowed for reduction ofcorticosteroid
dose administration in all cases (23). Amyloidosis in
TRAPS usually presents with nephrotic syndrome,
and early treatment of renal involvement with
corticosteroids, colchicine or chlorambucil usually
fails to prevent end-stage renal failure. Anecdotal
reports of successful treatment with etanercept of
patients with TRAPS characterized by nephrotic
syndrome have recently been described (24). In
addition, etanercept slowed the progression of renal
failure due to renal amyloidosis in an 18-year-old
patient who underwent renal transplantation at the
age of 14 (25).
In contrast, the administration of other anti-TNF
agents, such as infliximab, a mouse-human chimeric
monoclonal IgG1 antibody to TNF, or adalimumab,
a fully humanised anti-TNF monoclonal antibody,
'hlay lead to enhanced anti-apoptotic activity, over-
secretion of pro-inflammatory cytokines (IL-l,
IL-l R, IL-6, IL-8, and IL-12) (11) and paradoxical
exacerbation of the TRAPS clinical picture (12,
23, 26). Differences in response to treatment with
different TNF-inhibitors seem to be related to
the more stable binding complexes with soluble
TNF and to their much higher binding avidity to
transmembrane TNF of monoclonal antibodies than
etanercept (27). Moreover, it has been hypothesized
that mutations altering the extracellular conformation
of TNFR fail to shed infliximab-bound TNF/TNFR
from the cell surface, thus leading to the induction of
inflammatory responses (12).
A decrease in responsiveness to etanercept over
time has been described in few patients; the authors
hypothesized that etanercept efficacy in TRAPS
might be non-specific and may reflect 'generic' anti-
inflammatory properties of the molecule (28-29).
There are promising results deriving from the use
of anakinra, a recombinant interleukin-I receptor
antagonist, in etanercept-resistant patients; in
these patients, anakinra prevented disease relapses
in the short-term, raising the hypothesis that the
dysregulation of IL-l secretion might represent the
final common pathway ofdifferent autoinflammatory
diseases (30-31). To date, the initial results obtained
in patients with TRAPS through IL-l inhibition,
though promising, are restricted to very few cases
and must be subjected to further evaluation in larger
cohorts of patients.
Personal experience
To date, of the patients affected with TRAPS
whom we are treating with etanercept, 7 have
reached a 12-month follow-up. Six patients out
of 7 are adults (32-33), and 1 is of pediatric age
(34). Of the 6 adults, 4 were characterized by adult
disease-onset, whereas 2 reported the onset of
symptoms during childhood. Table I summarizes the
main characteristics of our cohort of patients. Four
patients out of 7 presented recurrent pericarditis as
the sole clinical manifestation (32), and of these,
3 carried the low-penetrance R92Q mutation in
TNFRSF1A. In addition, one of these patients
presenting with recurrent pericarditis as the sole
clinical manifestation carried a novel heterozygous
~YI03-R104 deletion in the exon 4, characterized
by a six-nucleotide heterozygous deletion (TACCGG
nucleotide sequence) and causing the loss of the
aminoacid tyrosine and arginine at position 103 and
104, respectively (32). The functional implication
of this deletion is currently under investigation in
our laboratories. One patient out of the 5 carrying
the R92Q mutation was characterized by an unusual
association of sacroileitis and pericarditis, in the
absence of the most typical clinical signs of TRAPS
(33). The R92Q mutation is common in patients
of Mediterranean origin, and in a recent study
its frequency in healthy Italian individuals was
2.25%. Moreover, in most of the R92Q patients,
the mutation was inherited from one healthy
parent (3). Nevertheless, its increased frequency
among patients with periodic fever suggests that it
is a low-penetrance mutation rather than a benign
polymorphism (9).
Although soluble TNFRSFIA serum levels
do not seem to increase with attacks, monocytes
from patients bearing the R92Q substitution show
TNFRSF 1A membrane staining and receptor
shedding comparable to controls, suggesting
that additional pathogenetic mechanisms may be
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operative in TRAPS (9). Recently, Lobito et al
reported that the R92Q variant TNFRSFIA behaves
like wild-type TNFRSFIA, with apparently normal
folding, identical surface expression and TNF binding
(10). The authors suggested that the pathogenesis of
TRAPS in patients harboring only the R92Q variant
is probably different from that of patients carrying
other mutations. The R92Q allele may therefore
cause milder disease, and may often be associated
with an oligosymptomatic course (16, 35).
The low-penetrance TNFRSFIA variant seems
to contribute to atypical inflammatory responses in
TRAPS, including cardiac diseases (myocarditis and
pericarditis) (17,32-33,36). In addition, we recently
further confirmed the potential role of mutations
in the TNFRSF1A gene in patients with recurrent
idiopathic pericarditis (37).
The pediatric patient, on the other hand, presented
with a severe clinical picture, although she carried
a low-penetrance D12E mutation characterized
by a T to G transition in exon 2 which substitutes
an aspartic acid for a glutamic acid at position 12
(Dl2E; c.123T>G). The D12E mutation was initially
supposed to determine a milder disease and also
a shorter duration of fever attacks (3). The same
mutation was subsequently described by Gattorno et
al. in a patient who was also carrying a homozygous
M680I mutation on the MEFV gene, responsible for
familial Mediterranean fever (FMF); that patient was
classified as having FMF (31).
Although missense substitutions of cysteine
or threonine residues are associated with a more
aggressive disease course (10), patients with severe
TRAPS caused by a non-cysteine mutation (T50M)
in the TNFRSFIA gene have been reported (2,
9, 25). The functional implication of the Dl2E
mutation is also currently under investigation in our
laboratories.
All 7 of our patients had previously been
treated with prednisone, and they required chronic
administration ofhigh doses in order to prevent flares
and achieve good disease control. In addition, SAA
circulating levels increased even during symptom-
free intervals. For these reasons, treatment with
etanercept was started.
Etanercept determined the resolution of fever
and of other disease-related clinical manifestations
and allowed the reduction of corticosteroid
administration, up to suspension in all cases. At
l-year follow-up, none of the patients showed any
sign of disease relapse and, in addition, SAA levels
checked at least three times were persistently within
normal range. Apart from skin reactions at the site
of the injections, which were observed in 2 out of 7
patients, no serious adverse events were observed.
CONCLUSIONS
To date, etanercept has been shown to be
efficacious in treating TRAPS in most cases; its
administration may prevent disease flares and/or
permit reduction of corticosteroid administration.
Anecdotal reports also describe its efficacy in the
treatment of TRAPS-related reactive amyloidosis.
Nevertheless, a decline in responsiveness may occur
in some cases. Among the TNF-n neutralizing agents,
infliximab and adalimumab may cause paradoxical
inflammatory attacks, and caution is strongly advised
when prescribing them to patients with TRAPS. In
etanercept-resistant patients, IL-l inhibition proved
successful. Though promising, the results obtained
with IL-l antagonists are, to date, limited to very few
cases and must undergo further evaluation in larger
cohorts ofpatients. Our data, although obtained with
patients carrying low-penetrance mutations (5/7)
and presenting incomplete disease (4/7), confirm
etanercept as a possible first-line treatment option in
the treatment of TRAPS. Nonetheless, the definite
role of etanercept in the management of TRAPS and
its long-term benefit and potential adverse effects
will be further assessed in large-scale trials.
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